Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 171

Sort by

Sort Order Select

Journal Articles

Survival Impact of Early Versus Late Discontinuation of Immunosuppression after Allogeneic Stem Cell Transplantation

Justin Laporte, Katelin Jackson, Xu Zhang, Asad Bashey, Lawrence E Morris, Lizamarie Bachier Rodriguez, Melhem M. Solh, Scott R. Solomon, H. Kent Holland

Blood (2024) 144 (Supplement 1): 7333.

https://doi.org/10.1182/blood-2024-200207

Published: 2024

Journal Articles

Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease

Scott R. Solomon, Melissa Sanacore, Lizamarie Bachier Rodriguez, Latasha McCoy, Caitlin Guzowski, Katelin C Jackson, Xu Zhang, H. Kent Holland, Lawrence E Morris, Melhem M. Solh, Asad Bashey

Blood (2024) 144 (Supplement 1): 3528.

https://doi.org/10.1182/blood-2024-199618

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Blood (2024) 144 (Supplement 1): 4633.

https://doi.org/10.1182/blood-2024-200840

Published: 2024

Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Blood (2024) 144 (Supplement 1): 72.

https://doi.org/10.1182/blood-2024-199813

Published: 2024

Journal Articles

Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center

Asad Bashey, Xu Zhang, Lawrence E Morris, H. Kent Holland, Lizamarie Bachier-Rodriguez, Scott R. Solomon, Melhem M. Solh

Blood (2024) 144 (Supplement 1): 1522.

https://doi.org/10.1182/blood-2024-209199

Published: 2024

Journal Articles

Intensive Conditioning with Fludarabine Plus Melphalan Versus Total Body Irradiation Prior to Haploidentical Transplant and Post-Transplant Cyclophosphamide

Scott R. Solomon, Melissa Sanacore, Asad Bashey, Katelin C Jackson, Lizamarie Bachier Rodriguez, Lawrence E Morris, H. Kent Holland, Melhem M. Solh

Blood (2024) 144 (Supplement 1): 3501.

https://doi.org/10.1182/blood-2024-200103

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Blood (2024) 144 (Supplement 1): 887.

https://doi.org/10.1182/blood-2024-200339

Published: 2024

Journal Articles

Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant

Asad Bashey, Xu Zhang, H. Kent Holland, Lawrence E Morris, Lizamarie Bachier-Rodriguez, Scott R. Solomon, Melhem M. Solh

Blood (2024) 144 (Supplement 1): 1450.

https://doi.org/10.1182/blood-2024-209117

Published: 2024

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J. Landsburg, Richard T. Maziarz, Amy Moskop, Leslie L. Popplewell, Scott R. Solomon, Michael T. Tees, Yongzi Yu, Aiesha Zia, Stephen Lim, Avishek Pal, Pei Hsu, Frederick Locke

Blood (2024) 144 (Supplement 1): 4398.

https://doi.org/10.1182/blood-2024-204207

Published: 2024

Journal Articles

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon E. Arnason, Manali Kamdar, David G. Maloney, Mazyar Shadman, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Juliana E. Hidalgo-López, Jing Wang, Ken Ogasawara, Ashvin Singh, Tanya Siddiqi

Blood (2024) 144 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2024-200204

Published: 2024

Journal Articles

Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma

Steven Baker, Asad Bashey, Lizamarie Bachier-Rodriguez, Lawrence E Morris, H Kent Holland, Justin Laporte, Scott R. Solomon, Melissa Sanacore, Melhem Solh

Blood (2024) 144 (Supplement 1): 2363.

https://doi.org/10.1182/blood-2024-210395

Published: 2024

Journal Articles

The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Melhem M. Solh, Asad Bashey, Michael T Aubrey, Brian Freed, Christina Roark, Lawrence E Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Scott R. Solomon

Blood (2024) 144 (Supplement 1): 4913.

https://doi.org/10.1182/blood-2024-210329

Published: 2024

Journal Articles

Extracorporeal Photopheresis (ECP) in the Era of New Chronic Graft-Versus-Disease (GVHD) Therapies

Melhem M. Solh, Asad Bashey, Lawrence E Morris, Lizamarie Bachier-Rodriguez, H. Kent Holland, Xu Zhang, Rajveer Singh, Katelin Jackson, Scott R. Solomon

Blood (2024) 144 (Supplement 1): 4912.

https://doi.org/10.1182/blood-2024-208659

Published: 2024

Journal Articles

High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Melhem M. Solh, Scott R. Solomon, Christina Roark, Michael T Aubrey, Lawrence E Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Brian Freed, Asad Bashey

Blood (2024) 144 (Supplement 1): 4948.

https://doi.org/10.1182/blood-2024-210627

Published: 2024

Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi

Blood (2024) 143 (5): 404–416.

https://doi.org/10.1182/blood.2023020854

Published: 2024

Includes: Supplemental data

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Maria Lia Palomba, Tanya Siddiqi, Leo I. Gordon, Manali Kamdar, Matthew A Lunning, Alexandre V Hirayama, Jeremy S. Abramson, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Michael L. Wang

Blood (2023) 142 (Supplement 1): 3505.

https://doi.org/10.1182/blood-2023-178109

Published: 2023

Journal Articles

Comparison of Condensed to Standard Schedule of High Dose Cytarabine Consolidation for Acute Myeloid Leukemia in First Complete Remission

Melhem M. Solh, Kristen Kilby, Jimena Baron, Xu Zhang, Asad Bashey, H Kent Holland, Lizamarie Bachier-Rodriguez, Lawrence Morris, Scott R. Solomon

Blood (2023) 142 (Supplement 1): 5939.

https://doi.org/10.1182/blood-2023-186662

Published: 2023

Journal Articles

Immunosuppression Free at One-Year Post Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Melhem M. Solh, Scott R. Solomon, Lawrence Morris, Lizamarie Bachier-Rodriguez, H Kent Holland, Xu Zhang, Katelin C Jackson, Asad Bashey

Blood (2023) 142 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2023-187505

Published: 2023

Journal Articles

Preliminary Results of the Oral CD73 Inhibitor, Oric-533, in Relapsed/Refractory Multiple Myeloma (RRMM)

Cesar Rodriguez, Scott R. Solomon, Barry Paul, Omar Nadeem, Meenal Patel, Jian Wang, Rongda Xu, Melissa Junttila, Anneleen Daemen, Subhash Katewa, Pratik S Multani, Wilson I. Gonsalves

Blood (2023) 142 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2023-173730

Published: 2023

Journal Articles

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Blood (2023) 142 (Supplement 1): 105.

https://doi.org/10.1182/blood-2023-180952

Published: 2023

NARROW

Survival Impact of Early Versus Late Discontinuation of Immunosuppression after Allogeneic Stem Cell Transplantation

Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center

Intensive Conditioning with Fludarabine Plus Melphalan Versus Total Body Irradiation Prior to Haploidentical Transplant and Post-Transplant Cyclophosphamide

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant

Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma

The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Extracorporeal Photopheresis (ECP) in the Era of New Chronic Graft-Versus-Disease (GVHD) Therapies

High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Comparison of Condensed to Standard Schedule of High Dose Cytarabine Consolidation for Acute Myeloid Leukemia in First Complete Remission

Immunosuppression Free at One-Year Post Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Preliminary Results of the Oral CD73 Inhibitor, Oric-533, in Relapsed/Refractory Multiple Myeloma (RRMM)

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only